Skip to main content

Table 3 3-O-methyl glucose absorption: post-dose vs. baseline comparison (excluding the n = 2 without adequate camicinal exposures)

From: The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial

Plasma 3-OMG Comparison Baseline Post study drug Point estimate 95 % CI
(mean) (mean)
AUC(0–240) (mmol.min/L)* 50 mg (n = 15) 28.630 71.632 2.502 (1.683, 3.719)
50 mg (n = 13)# 33.042 74.587 2.257 (1.478, 3.449)
75 mg (n = 6) 48.373 35.048 0.725 (0.387, 1.356)
Placebo (n = 12) 45.791 60.699 1.326 (0.851, 2.065)
AUC(0–60) (mmol.min/L)* 50 mg (n = 15) 2.962 11.646 3.932 (2.037, 7.588)
50 mg (n = 13)# 3.779 12.390 3.279 (1.631, 6.592)
75 mg (n = 6) 9.698 4.914 0.507 (0.179, 1.433)
Placebo (n = 12) 5.935 7.464 1.258 (0.603, 2.623)
Cmax (mmol/L)* 50 mg (n = 15) 0.1905 0.4287 2.2505 (1.5736, 3.2186)
50 mg (n = 13)# 0.2107 0.4496 2.1344 (1.4389, 3.1662)
75 mg (n = 6) 0.3530 0.2512 0.7116 (0.4042, 1.2530)
Placebo (n = 12) 0.3035 0.3824 1.2600 (0.8446, 1.8797)
  1. 3-OMG 3-O-methyl glucose, CI confidence interval, AUC area under the curve, Cmax peak 3-OMG concentration
  2. *Log-transformed
  3. #Two subjects administered 50 mg camicinal had low drug exposure. Analyses were performed with and without these subjects